Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy

Cardiology Journal

Volumn 16, Issue 2, 2009, Pages 172-174

  Keivanidou, Anastasia ^a   Arnaoutoglou, Christos ^b   Krommydas, Argyrios ^a   Papanikolaou, Georgios ^a   Tsiptses, Konstantinos ^a   Chrisopoulos, Charalampos ^a   Kirpizidis, Christos ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Amiodarone; Ciprofloxacin; Long QT; Sotalol; Torsades de pointes

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BILIRUBIN; BILIRUBIN GLUCURONIDE; CIPROFLOXACIN; DIGOXIN; MAGNESIUM; POTASSIUM; POTASSIUM CHANNEL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; ANTIINFECTIVE AGENT;

AGED; ARTICLE; CASE REPORT; CHOLECYSTITIS; DEFIBRILLATION; DRUG WITHDRAWAL; FEMALE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; LOADING DRUG DOSE; LONG QT SYNDROME; POTASSIUM BLOOD LEVEL; RECURRENT DISEASE; SYNCOPE; TORSADE DES POINTES; CARDIOVERSION; CHEMICALLY INDUCED DISORDER; ELECTROCARDIOGRAPHY; TREATMENT OUTCOME;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTI-INFECTIVE AGENTS; ATRIAL FIBRILLATION; CIPROFLOXACIN; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; HEART ARREST; HUMANS; LONG QT SYNDROME; SOTALOL; SYNCOPE; TORSADES DE POINTES; TREATMENT OUTCOME;

EID: 66349110617     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Prabhakar M, Krahn AD. Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm, 2004; 5: 624-626.
2. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents, 2007; 29: 374-379.
3. Patmore L, Fraser S, Mair D, Templeton A. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur J Pharmacol, 2000; 406: 449-452.
4. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther, 2003; 73: 292-303.
5. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol, 2006; 11: 52-56.
6. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy, 2001; 21: 1468-1472.
7. Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B. Effect of ciprofloxacin and levofloxacin on the QT interval: Is this a significant "clinical" event? South Med J, 2006; 99: 52-56.
8. Zipes DP, Libby P, Bonow R, Braunwald E eds. Braunwald's heart disease. A textbook of cardiovascular medicine. 7th Ed. Elsevier-Saunders, Philadelphia 2005.
9. Cubeddu LX. QT prolongation and fatal arrhythmias: A review of clinical implications and effects of drugs. Am J Ther, 2003; 10: 452-457.
10. Owens RC Jr, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy, 2002; 22: 663-668.
11. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther, 2004; 75: 242-247.
12. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf, 2002; 1: 121-128.